Table 2 New standard of care treatment with telaprevir for chronic hepatitis C patients
From: Treatment of hepatitis C virus infection in the future
References | G | Number of patients | Naïve or re-treatment | Formula of therapy, and duration of treatment (weeks) | SVR rates (%) | Notes |
|---|---|---|---|---|---|---|
[35] | G1 | 79 | naive | T12PR24 | 61 | PROVE1 Study |
79 | naive | T12PR48 | 67 | |||
17 | naive | T12PR12 | 35 | |||
75 | naive | PR48 | 41 | |||
[36] | G1 | 81 | naive | T12PR24 | 69 | PROVE2 Study |
82 | naive | T12PR12 | 60 | |||
78 | naive | T12P12 | 36 | |||
42 | naive | PR48 | 46 | |||
[37] | G1 | 115 | re-treatment | T12PR24 | 51 | PROVE3 Study |
113 | re-treatment | T12PR48 | 53 | |||
111 | re-treatment | T24P24 | 24 | |||
114 | re-treatment | PR48 | 14 | |||
[38] | G1 | 363 | naive | T12PR | 73 | ADVANCE Study |
| Â | Â | 364 | naive | T8PR | 67 | |
|  |  | 49 | naïve | PR48 | 44 | |
[39] | G1 | 145 | re-treatment | T12PR48 | 93 | REALIZE Study |
| Â | Â | 141 | re-treatment | Lead-in T12 PR48 | 89 | |
| Â | Â | 68 | re-treatment | PR48 | 24 | |
[40] | G1 | 162 | naïve | T12PR24 (RGT) | 92 | ILLUMINATE Study |
|  |  | 160 | naïve | T12PR48 (RGT) | 88 | |
|  |  | 118 | naïve | T12PR48 (non-RGT) | 64 | |
|  |  | 100 | naïve | Discontinued treatment before wk 20 | 23 |  |